In a major endorsement of Telangana's burgeoning Life Sciences ecosystem, US pharmaceutical powerhouse Eli Lilly and Company has pledged over $1 billion to establish cutting-edge contract manufacturing facilities in Hyderabad. This strategic expansion will amplify the state's role as a global hub for innovative drug production, targeting treatments for diabetes, obesity, Alzheimer's, cancer, and autoimmune disorders, while generating thousands of high-skilled jobs for the region's youth.

The announcement followed a high-level meeting at the state's Integrated Command Control Centre, where Eli Lilly's global delegation engaged with Chief Minister A. Revanth Reddy and Industries Minister D. Sridhar Babu. Despite overtures from multiple states, the company selected Telangana for its unmatched blend of skilled talent, world-class infrastructure, and proactive governance—qualities that extend beyond the Global Capability Centre (GCC) inaugurated by the Chief Minister on August 4.

"This investment underscores Eli Lilly's deepening commitment to Telangana, evolving from capability centers to pioneering therapies that address humanity's most pressing health challenges," said Patrik Jonsson, Executive Vice President and President of Lilly International. "It reaffirms our faith in India as a cornerstone of our global innovation network."

Recruitment kicks off immediately, spanning roles in engineering, chemistry, analytical sciences, quality assurance, and executive leadership. The facilities will enable contract manufacturing for worldwide distribution, positioning Hyderabad at the forefront of advanced healthcare supply chains. Chief Minister Revanth Reddy hailed the move as a testament to Telangana's industrial renaissance, tracing its roots to Indira Gandhi's 1965 establishment of Indian Drugs and Pharmaceuticals Limited (IDPL) in Hyderabad—the cradle of India's bulk drug prowess and a key player in global COVID-19 vaccine production. "Telangana means business. Hyderabad is a global city, and our government stands ready to champion every investor's vision," he stressed. Industries Minister Sridhar Babu echoed this enthusiasm, calling the expansion "a resounding vote of confidence in our dynamic landscape for next-generation healthcare manufacturing."

To sustain this momentum, the government is advancing Telangana as a knowledge epicenter, with a new Advanced Technology Centre (ATC) rising in Genome Valley for R&D support. Renowned pharma leaders, including Anand Mahindra as chairperson, now guide the Young India Skills University, ensuring a pipeline of world-ready talent.

This infusion not only crowns one of India's largest recent pharma commitments but also cements Telangana's ascent as an indispensable node in the global life sciences value chain—driving innovation, employment, and economic vitality.